Acumen Pharmaceuticals, Inc.
ABOS
$2.72
$0.041.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -78.12% | 63.99% | 120.01% | 131.50% | 121.65% |
| Gross Profit | 78.12% | -63.99% | -120.01% | -131.50% | -121.65% |
| SG&A Expenses | -6.29% | -5.31% | -2.23% | 1.39% | 7.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.61% | 48.78% | 87.77% | 92.49% | 86.49% |
| Operating Income | -8.61% | -48.78% | -87.77% | -92.49% | -86.49% |
| Income Before Tax | -18.57% | -63.28% | -110.69% | -107.83% | -95.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.57% | -63.28% | -110.69% | -107.83% | -95.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.57% | -63.28% | -110.69% | -107.83% | -95.39% |
| EBIT | -8.61% | -48.78% | -87.77% | -92.49% | -86.49% |
| EBITDA | -8.62% | -48.83% | -87.85% | -92.58% | -86.57% |
| EPS Basic | -17.56% | -61.05% | -103.41% | -83.07% | -57.53% |
| Normalized Basic EPS | -17.57% | -61.08% | -103.45% | -83.09% | -57.51% |
| EPS Diluted | -17.56% | -61.05% | -103.41% | -83.07% | -57.53% |
| Normalized Diluted EPS | -17.57% | -61.08% | -103.45% | -83.09% | -57.51% |
| Average Basic Shares Outstanding | 0.91% | 1.58% | 3.93% | 12.99% | 23.55% |
| Average Diluted Shares Outstanding | 0.91% | 1.58% | 3.93% | 12.99% | 23.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |